Last reviewed · How we verify

NCT04649840

Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients

Completed Last updated 10 December 2021
What this trial tests

trial testing Humoral and cellular immunity in Covid19 in 274 participants. Completed in 9 December 2021.

Timeline
1 October 2020
Primary endpoint
9 December 2021
9 December 2021

Quick facts

Lead sponsorInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
StatusCompleted
Study typeOBSERVATIONAL
Enrollment274
Start date1 October 2020
Primary completion9 December 2021
Estimated completion9 December 2021
Sites1 location across Belarus

Drugs / interventions tested

Conditions studied

Sponsor

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of the project: to study the dynamics of the humoral and cellular immunity in patients after pneumonia caused by the SARS-CoV-2 virus at different time intervals, in order to predict the duration of immune protection

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04649840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing